175 related articles for article (PubMed ID: 31290692)
1. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A
CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692
[No Abstract] [Full Text] [Related]
2. High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Marinelli A; Lamberti G; Cerbone L; Cordua N; Buonerba C; Peluso G; Di Lorenzo G; De Placido S
Medicine (Baltimore); 2018 Jul; 97(27):e11254. PubMed ID: 29979390
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V
J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580
[TBL] [Abstract][Full Text] [Related]
4. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
[TBL] [Abstract][Full Text] [Related]
6. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
[TBL] [Abstract][Full Text] [Related]
8. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S
J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
[TBL] [Abstract][Full Text] [Related]
11. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
[TBL] [Abstract][Full Text] [Related]
12. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
[TBL] [Abstract][Full Text] [Related]
13. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
14. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
Vaccaro V; Fabi A; Vidiri A; Giannarelli D; Metro G; Telera S; Vari S; Piludu F; Carosi MA; Villani V; Cognetti F; Pompili A; Marucci L; Carapella CM; Pace A
Biomed Res Int; 2014; 2014():351252. PubMed ID: 24877084
[TBL] [Abstract][Full Text] [Related]
16. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Boiardi A; Silvani A; Ciusani E; Watson A; Margison G; Berger E; Lucas C; Giroux B
J Neurooncol; 2001 Apr; 52(2):149-56. PubMed ID: 11508814
[TBL] [Abstract][Full Text] [Related]
17. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
18. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
Gallo C; Buonerba C; Di Lorenzo G; Romeo V; De Placido S; Marinelli A
J Neurooncol; 2010 Nov; 100(2):311-9. PubMed ID: 20556481
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
[TBL] [Abstract][Full Text] [Related]
20. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
